{
    "root": "34298d94-75d5-458c-e063-6294a90af929",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Losartan Potassium",
    "value": "20250502",
    "ingredients": [
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "2165RE0K14"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "LOSARTAN POTASSIUM",
            "code": "3ST302B24A"
        }
    ],
    "indications": "Losartan potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 )",
    "contraindications": "Hypertension •  Usual adult dose: 50 mg once daily. ( 2.1 ) •  Usual pediatric starting dose: 0.7 mg per kg once daily (up to 50 mg). ( 2.1 ) Hypertensive Patients with Left Ventricular Hypertrophy •  Usual starting dose: 50 mg once daily. ( 2.2 ) •  Add hydrochlorothiazide 12.5 mg and/or increase losartan potassium tablets to 100 mg followed by an increase to hydrochlorothiazide 25 mg if further blood pressure response is needed. ( 2.2 , 14.2 ) Nephropathy in Type 2 Diabetic Patients •  Usual dose: 50 mg once daily. ( 2.3 ) •  Increase dose to 100 mg once daily if further blood pressure response is needed. ( 2.3 )",
    "warningsAndPrecautions": "Losartan potassium tablets USP are supplied as follows:\n                  Losartan Potassium Tablets USP, 25 mg are green colored, oval shaped, biconvex film-coated tablets debossed with ‘E’ on one side and ‘45’ on other side.\n                  \n                  NDC: 70518-0959-00\n                  PACKAGIGN: 30 in 1 BLISTER PACK\n                  \n                  Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Keep container tightly closed. Protect from light.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "Losartan potassium tablets are contraindicated:\n                  \n                     In patients who are hypersensitive to any component of this product.\n                     For coadministration with aliskiren in patients with diabetes."
}